[
  {
    "objectID": "QUARTO_SETUP.html",
    "href": "QUARTO_SETUP.html",
    "title": "Quarto Multi-Page Site Setup",
    "section": "",
    "text": "This document describes the Quarto configuration for the maladie health tracking website.\n\n\nThe site is now a multi-page Quarto website with the following pages:\n\nHome (/ or /index.html) - The main page from README.md containing supplement schedule and health goals\nBlood Markers (/blood.html) - Interactive blood test results visualization\nMedications (/meds.html) - Medication and supplementation timeline visualization\n\n\n\n\n\n\n\n_quarto.yml - Main Quarto configuration file\n\n\n\n\n\nindex.qmd - Copy of README.md, serves as the home page\nblood.qmd - Page that embeds the blood markers visualization\nmeds.qmd - Page that embeds the medications timeline\n\n\n\n\n\nblood_markers.html - Original index.html with blood markers analysis\nmeds.html - Copy of meds_and_supplements/meds.html\n\n\n\n\n\nblood_markers_pivot.csv - Blood test data\nreports.json - Medical reports metadata\nmeds_and_supplements/med_schedule.json - Medication schedule data\n\n\n\n\n\nTo rebuild the site after making changes:\nquarto render\nThis will regenerate all HTML files in the docs/ directory.\n\n\n\nThe site is configured to deploy to GitHub Pages from the docs/ directory.\n\n\n\nGo to repository Settings ‚Üí Pages\nSet Source to ‚ÄúDeploy from a branch‚Äù\nSet Branch to ‚Äúmain‚Äù (or your default branch)\nSet Folder to ‚Äú/docs‚Äù\nSave\n\nThe site will be available at: https://maladie.ronaldo.tech\n\n\n\n\n\n\n\nCreate a new .qmd file in the root directory\nAdd the page to the navbar in _quarto.yml\nRun quarto render to regenerate the site\n\n\n\n\n\nUpdate CSV/JSON files in the root directory\nThe data files are automatically copied to docs/ during render\nRun quarto render to update\n\n\n\n\n\nEdit blood_markers.html or meds.html\nRun quarto render to copy changes to docs/"
  },
  {
    "objectID": "QUARTO_SETUP.html#structure",
    "href": "QUARTO_SETUP.html#structure",
    "title": "Quarto Multi-Page Site Setup",
    "section": "",
    "text": "The site is now a multi-page Quarto website with the following pages:\n\nHome (/ or /index.html) - The main page from README.md containing supplement schedule and health goals\nBlood Markers (/blood.html) - Interactive blood test results visualization\nMedications (/meds.html) - Medication and supplementation timeline visualization"
  },
  {
    "objectID": "QUARTO_SETUP.html#files-created",
    "href": "QUARTO_SETUP.html#files-created",
    "title": "Quarto Multi-Page Site Setup",
    "section": "",
    "text": "_quarto.yml - Main Quarto configuration file\n\n\n\n\n\nindex.qmd - Copy of README.md, serves as the home page\nblood.qmd - Page that embeds the blood markers visualization\nmeds.qmd - Page that embeds the medications timeline\n\n\n\n\n\nblood_markers.html - Original index.html with blood markers analysis\nmeds.html - Copy of meds_and_supplements/meds.html\n\n\n\n\n\nblood_markers_pivot.csv - Blood test data\nreports.json - Medical reports metadata\nmeds_and_supplements/med_schedule.json - Medication schedule data"
  },
  {
    "objectID": "QUARTO_SETUP.html#building-the-site",
    "href": "QUARTO_SETUP.html#building-the-site",
    "title": "Quarto Multi-Page Site Setup",
    "section": "",
    "text": "To rebuild the site after making changes:\nquarto render\nThis will regenerate all HTML files in the docs/ directory."
  },
  {
    "objectID": "QUARTO_SETUP.html#deployment",
    "href": "QUARTO_SETUP.html#deployment",
    "title": "Quarto Multi-Page Site Setup",
    "section": "",
    "text": "The site is configured to deploy to GitHub Pages from the docs/ directory.\n\n\n\nGo to repository Settings ‚Üí Pages\nSet Source to ‚ÄúDeploy from a branch‚Äù\nSet Branch to ‚Äúmain‚Äù (or your default branch)\nSet Folder to ‚Äú/docs‚Äù\nSave\n\nThe site will be available at: https://maladie.ronaldo.tech"
  },
  {
    "objectID": "QUARTO_SETUP.html#maintenance",
    "href": "QUARTO_SETUP.html#maintenance",
    "title": "Quarto Multi-Page Site Setup",
    "section": "",
    "text": "Create a new .qmd file in the root directory\nAdd the page to the navbar in _quarto.yml\nRun quarto render to regenerate the site\n\n\n\n\n\nUpdate CSV/JSON files in the root directory\nThe data files are automatically copied to docs/ during render\nRun quarto render to update\n\n\n\n\n\nEdit blood_markers.html or meds.html\nRun quarto render to copy changes to docs/"
  },
  {
    "objectID": "reports/Health_Report.html",
    "href": "reports/Health_Report.html",
    "title": "Maladie - Health Tracking",
    "section": "",
    "text": "1. Acute Hepatic Crisis (September 12, 2025) Your most recent blood work shows a dramatic deterioration in liver function markers, with what appears to be a severe hepatobiliary crisis. This coincides precisely with your reported symptoms of fatigue, inflammation, excessive urination, and diarrhea.\n2. Cholestatic Pattern The elevation pattern suggests cholestatic injury (bile duct inflammation/obstruction) rather than pure hepatocellular damage, which is consistent with PSC exacerbation. The disproportionate rise in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) compared to transaminases is classic for biliary tract pathology.\n3. Post-Infectious Complications The timeline is critical here: - August 5-14: Cholangitis hospitalization (bacterial infection of bile ducts) - August 31: C. difficile infection with UC flare - September 12: Acute decompensation\nThis sequence suggests you may be experiencing: - Recurrent cholangitis or incomplete resolution of the initial infection - PSC stricture progression triggered by recent infections - Post-infectious inflammatory response affecting both IBD and PSC\n\n\n\n\nRecurrent Ascending Cholangitis: The sudden enzyme elevation with systemic symptoms strongly suggests another episode of cholangitis, possibly due to bacterial seeding during your recent infections.\nDominant Stricture Development: PSC can develop dominant strictures that cause acute obstruction, leading to the dramatic enzyme elevations you‚Äôre experiencing.\nDrug-Induced Hepatotoxicity: If you received antibiotics for C. diff (likely vancomycin or fidaxomicin), there could be a component of medication-related liver injury, though this seems less likely given the cholestatic pattern.\nOverlap Syndrome Flare: The combination of UC flare and PSC exacerbation can create a severe inflammatory cascade affecting multiple organ systems.\n\n\n\n\nImmediate Concerns: - The multi-fold increase in liver enzymes with systemic symptoms suggests active biliary sepsis or severe cholestasis requiring urgent intervention - The fluid shifts (edema followed by diuresis) suggest possible hepatic decompensation\nShort-term Prognosis: With appropriate treatment, acute cholangitis typically responds well to antibiotics and biliary drainage if needed. However, given your recent infection history, you may need: - Extended antibiotic therapy - MRCP or ERCP to evaluate for dominant strictures - Possible biliary intervention (stenting/dilation)\nLong-term Considerations: - Recurrent cholangitis episodes accelerate PSC progression - Your young age at diagnosis (20) and now 20 years of disease duration puts you at higher risk for cirrhosis and need for transplant evaluation - The recent pattern of infections suggests your disease may be entering a more aggressive phase\nURGENT: You should seek immediate medical evaluation, preferably at a center with hepatology expertise. The combination of markedly elevated liver enzymes, systemic symptoms, and your PSC history warrants urgent assessment for cholangitis and possible biliary intervention."
  },
  {
    "objectID": "reports/Health_Report.html#section",
    "href": "reports/Health_Report.html#section",
    "title": "Maladie - Health Tracking",
    "section": "",
    "text": "1. Acute Hepatic Crisis (September 12, 2025) Your most recent blood work shows a dramatic deterioration in liver function markers, with what appears to be a severe hepatobiliary crisis. This coincides precisely with your reported symptoms of fatigue, inflammation, excessive urination, and diarrhea.\n2. Cholestatic Pattern The elevation pattern suggests cholestatic injury (bile duct inflammation/obstruction) rather than pure hepatocellular damage, which is consistent with PSC exacerbation. The disproportionate rise in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) compared to transaminases is classic for biliary tract pathology.\n3. Post-Infectious Complications The timeline is critical here: - August 5-14: Cholangitis hospitalization (bacterial infection of bile ducts) - August 31: C. difficile infection with UC flare - September 12: Acute decompensation\nThis sequence suggests you may be experiencing: - Recurrent cholangitis or incomplete resolution of the initial infection - PSC stricture progression triggered by recent infections - Post-infectious inflammatory response affecting both IBD and PSC\n\n\n\n\nRecurrent Ascending Cholangitis: The sudden enzyme elevation with systemic symptoms strongly suggests another episode of cholangitis, possibly due to bacterial seeding during your recent infections.\nDominant Stricture Development: PSC can develop dominant strictures that cause acute obstruction, leading to the dramatic enzyme elevations you‚Äôre experiencing.\nDrug-Induced Hepatotoxicity: If you received antibiotics for C. diff (likely vancomycin or fidaxomicin), there could be a component of medication-related liver injury, though this seems less likely given the cholestatic pattern.\nOverlap Syndrome Flare: The combination of UC flare and PSC exacerbation can create a severe inflammatory cascade affecting multiple organ systems.\n\n\n\n\nImmediate Concerns: - The multi-fold increase in liver enzymes with systemic symptoms suggests active biliary sepsis or severe cholestasis requiring urgent intervention - The fluid shifts (edema followed by diuresis) suggest possible hepatic decompensation\nShort-term Prognosis: With appropriate treatment, acute cholangitis typically responds well to antibiotics and biliary drainage if needed. However, given your recent infection history, you may need: - Extended antibiotic therapy - MRCP or ERCP to evaluate for dominant strictures - Possible biliary intervention (stenting/dilation)\nLong-term Considerations: - Recurrent cholangitis episodes accelerate PSC progression - Your young age at diagnosis (20) and now 20 years of disease duration puts you at higher risk for cirrhosis and need for transplant evaluation - The recent pattern of infections suggests your disease may be entering a more aggressive phase\nURGENT: You should seek immediate medical evaluation, preferably at a center with hepatology expertise. The combination of markedly elevated liver enzymes, systemic symptoms, and your PSC history warrants urgent assessment for cholangitis and possible biliary intervention."
  },
  {
    "objectID": "reports/20250925_TB_Interferon.html",
    "href": "reports/20250925_TB_Interferon.html",
    "title": "Gama-Interferon",
    "section": "",
    "text": "Gama-Interferon\n\nResultado: Negativo\n\n\nNIL: 0 07 UI/mL\nAnt√≠geno TB1 menos NIL: Inferior a 0,01 UI/mL\nAnt√≠geno TB2 menos NIL: Inferior a 0,01 UI/mL\nMit√≥geno menos NIL: Superior a 10,00 UI/mL"
  },
  {
    "objectID": "reports/20250918_Bi√≥psia_C√≥lon.html",
    "href": "reports/20250918_Bi√≥psia_C√≥lon.html",
    "title": "Conclus√£o",
    "section": "",
    "text": "Mucosa ileal com arquitetura preservada.\n\n\nN√£o foram detectados granulomas, parasitas, criptite, microabscessos de criptas e/ou displasia.\n\n\n\n\n\n‚ö†Ô∏è Colite ativa focal.\n\n\n\nMucosa col√¥nica com discretos microabscessos de cripta focais.\n\nN√£o foram detectados granulomas, parasitas, criptite e/ou displasia.\n\n\n\n\n\n‚ö†Ô∏èColite cr√¥nica leve.\n\n\n\nMucosa col√¥nica com discreta distor√ß√£o de criptas, criptite e microabscessos de criptas.\n\nN√£o foram detectados granulomas, parasitas e/ou displasia.\n\n\n\n\n\n‚ö†Ô∏èRetite cr√¥nica leve.\n\n\n\nMucosa retal com discreta distor√ß√£o de criptas, criptite e microabscessos de criptas.\n\nN√£o foram detectados granulomas, parasitas e/ou displasia.\n\nNota: √â necess√°ria correla√ß√£o com dados cl√≠nicos, laboratoriais e colonosc√≥picos."
  },
  {
    "objectID": "reports/20250918_Bi√≥psia_C√≥lon.html#bi√≥psia-de-√≠leo-terminal",
    "href": "reports/20250918_Bi√≥psia_C√≥lon.html#bi√≥psia-de-√≠leo-terminal",
    "title": "Conclus√£o",
    "section": "",
    "text": "Mucosa ileal com arquitetura preservada.\n\n\nN√£o foram detectados granulomas, parasitas, criptite, microabscessos de criptas e/ou displasia."
  },
  {
    "objectID": "reports/20250918_Bi√≥psia_C√≥lon.html#bi√≥psia-de-c√≥lon-direito",
    "href": "reports/20250918_Bi√≥psia_C√≥lon.html#bi√≥psia-de-c√≥lon-direito",
    "title": "Conclus√£o",
    "section": "",
    "text": "‚ö†Ô∏è Colite ativa focal.\n\n\n\nMucosa col√¥nica com discretos microabscessos de cripta focais.\n\nN√£o foram detectados granulomas, parasitas, criptite e/ou displasia."
  },
  {
    "objectID": "reports/20250918_Bi√≥psia_C√≥lon.html#spa25-164481c---bi√≥psia-de-c√≥lon-esquerdo",
    "href": "reports/20250918_Bi√≥psia_C√≥lon.html#spa25-164481c---bi√≥psia-de-c√≥lon-esquerdo",
    "title": "Conclus√£o",
    "section": "",
    "text": "‚ö†Ô∏èColite cr√¥nica leve.\n\n\n\nMucosa col√¥nica com discreta distor√ß√£o de criptas, criptite e microabscessos de criptas.\n\nN√£o foram detectados granulomas, parasitas e/ou displasia."
  },
  {
    "objectID": "reports/20250918_Bi√≥psia_C√≥lon.html#spa25-164481d---bi√≥psia-de-reto",
    "href": "reports/20250918_Bi√≥psia_C√≥lon.html#spa25-164481d---bi√≥psia-de-reto",
    "title": "Conclus√£o",
    "section": "",
    "text": "‚ö†Ô∏èRetite cr√¥nica leve.\n\n\n\nMucosa retal com discreta distor√ß√£o de criptas, criptite e microabscessos de criptas.\n\nN√£o foram detectados granulomas, parasitas e/ou displasia.\n\nNota: √â necess√°ria correla√ß√£o com dados cl√≠nicos, laboratoriais e colonosc√≥picos."
  },
  {
    "objectID": "colesterol.html",
    "href": "colesterol.html",
    "title": "Metabolismo do Colesterol e Colestase Hep√°tica",
    "section": "",
    "text": "Colesterol na Colestase\n\n\n\n\n\nMapa Colesterol\n\n\n\n\n\nNa colestase (PBC/PSC), o colesterol total sobe muito, dominado por LpX (n√£o aterog√™nica e n√£o captada por LDLR).\nA disfun√ß√£o do fluxo biliar reduz convers√£o em √°cidos biliares e bloqueia excre√ß√£o, levando a ac√∫mulo hep√°tico e feedback desregulado (‚Üë s√≠ntese).\nO risco CV n√£o aumenta proporcionalmente ao total, por causa do peso da LpX; me√ßa ApoB/LDL verdadeiro para risco aterog√™nico real.\nConduta: tratar a colestase (UDCA/desobstru√ß√£o/transplante); resinas para prurido; considerar estatina/fibrato se ApoB/LDL aterog√™nico estiverem elevados."
  },
  {
    "objectID": "colesterol.html#mini-guia-cl√≠nico-em-4-linhas-foco-em-colesterol-total",
    "href": "colesterol.html#mini-guia-cl√≠nico-em-4-linhas-foco-em-colesterol-total",
    "title": "Metabolismo do Colesterol e Colestase Hep√°tica",
    "section": "",
    "text": "Na colestase (PBC/PSC), o colesterol total sobe muito, dominado por LpX (n√£o aterog√™nica e n√£o captada por LDLR).\nA disfun√ß√£o do fluxo biliar reduz convers√£o em √°cidos biliares e bloqueia excre√ß√£o, levando a ac√∫mulo hep√°tico e feedback desregulado (‚Üë s√≠ntese).\nO risco CV n√£o aumenta proporcionalmente ao total, por causa do peso da LpX; me√ßa ApoB/LDL verdadeiro para risco aterog√™nico real.\nConduta: tratar a colestase (UDCA/desobstru√ß√£o/transplante); resinas para prurido; considerar estatina/fibrato se ApoB/LDL aterog√™nico estiverem elevados."
  },
  {
    "objectID": "reports/20250913_Relatorio_Clinico.html",
    "href": "reports/20250913_Relatorio_Clinico.html",
    "title": "Maladie - Health Tracking",
    "section": "",
    "text": "Inflama√ß√£o (PCR / Prote√≠na C Reativa):\n\nSubiu com a infec√ß√£o/flare, mas vem caindo aos poucos de picos (~8‚Äì9 mg/dL) para cerca de 6,3 mg/dL em 16/09.\nIndica que a inflama√ß√£o ainda existe, mas est√° diminuindo.\n\nLeuc√≥citos:\n\nEstavam elevados (&gt;15 mil) durante a infec√ß√£o.\nAgora ca√≠ram para ~9,7 mil em 16/09, perto da faixa normal.\nSugere melhora da atividade infecciosa/inflamat√≥ria.\n\nPlaquetas:\n\nSubiram de ~410 mil ‚Üí quase 490 mil.\nIsso √© comum em inflama√ß√£o persistente ou estresse hep√°tico (trombocitose reativa).\nN√£o preocupa isoladamente, mas mostra que o organismo ainda est√° em estado pr√≥-inflamat√≥rio.\n\nEnzimas hep√°ticas:\n\nAST (TGO), ALT (TGP), GGT e Fosfatase Alcalina tiveram eleva√ß√£o acentuada no epis√≥dio de colestase.\nAgora parecem estabilizadas ou em leve queda, em linha com a resson√¢ncia (sem colangite aguda).\nO Tozacin pode estar ajudando a prevenir infec√ß√£o secund√°ria, enquanto a pr√≥pria PSC mant√©m as enzimas altas.\n\nBilirrubina:\n\nEst√° elevada, mas sem piora recente.\nBilirrubina est√°vel + PCR em queda √© sinal de que n√£o h√° piora obstrutiva/infecciosa no momento.\n\n\n\n\n\n\nA infec√ß√£o por C. difficile (in√≠cio de setembro) desencadeou inflama√ß√£o sist√™mica e provavelmente precipitou o flare da RCU.\nA PSC complicou o quadro: as enzimas subiram, mas a resson√¢ncia afastou nova obstru√ß√£o.\nOs m√©dicos entraram com antibi√≥tico de amplo espectro (Tozacin) para proteger contra colangite bacteriana ‚Äî conduta razo√°vel considerando seu hist√≥rico (colangite aguda no in√≠cio de agosto).\nAgora, os exames sugerem:\n\nInfec√ß√£o sob controle (queda de leuc√≥citos e PCR).\nColite ulcerativa ainda ativa, mas melhorando.\nPSC est√°vel, sem sinais de piora aguda.\n\n\n\n\n\n\nNesta semana: PCR e leuc√≥citos devem se aproximar da normalidade se a infec√ß√£o estiver realmente controlada.\n1‚Äì2 semanas: Enzimas hep√°ticas podem continuar altas, mas devem cair gradualmente se n√£o houver nova colangite.\nColite ulcerativa: a melhora pode demorar mais (algumas semanas), especialmente se houver ajuste de corticoide/biol√≥gicos.\nPSC: risco cr√¥nico ‚Äî objetivo √© estabilizar, n√£o normalizar completamente.\n\n\n\n\n\nSe enzimas hep√°ticas subirem novamente + febre ‚Üí suspeita de nova colangite.\nSe PCR n√£o cair ou plaquetas continuarem subindo ‚Üí pode indicar inflama√ß√£o cont√≠nua ou complica√ß√£o secund√°ria.\nSe bilirrubina aumentar muito ‚Üí pode haver nova obstru√ß√£o ou evento biliar.\n\n‚úÖ Resumo: Voc√™ est√° na fase de melhora da tempestade inflamat√≥ria/infecciosa: a C. diff e o flare da colite desencadearam o quadro, mas os antibi√≥ticos e o suporte hospitalar estabilizaram. A expectativa √© de melhora lenta e progressiva nas pr√≥ximas 1‚Äì2 semanas, desde que n√£o ocorra nova colangite ou reativa√ß√£o da RCU."
  },
  {
    "objectID": "reports/20250913_Relatorio_Clinico.html#section",
    "href": "reports/20250913_Relatorio_Clinico.html#section",
    "title": "Maladie - Health Tracking",
    "section": "",
    "text": "Inflama√ß√£o (PCR / Prote√≠na C Reativa):\n\nSubiu com a infec√ß√£o/flare, mas vem caindo aos poucos de picos (~8‚Äì9 mg/dL) para cerca de 6,3 mg/dL em 16/09.\nIndica que a inflama√ß√£o ainda existe, mas est√° diminuindo.\n\nLeuc√≥citos:\n\nEstavam elevados (&gt;15 mil) durante a infec√ß√£o.\nAgora ca√≠ram para ~9,7 mil em 16/09, perto da faixa normal.\nSugere melhora da atividade infecciosa/inflamat√≥ria.\n\nPlaquetas:\n\nSubiram de ~410 mil ‚Üí quase 490 mil.\nIsso √© comum em inflama√ß√£o persistente ou estresse hep√°tico (trombocitose reativa).\nN√£o preocupa isoladamente, mas mostra que o organismo ainda est√° em estado pr√≥-inflamat√≥rio.\n\nEnzimas hep√°ticas:\n\nAST (TGO), ALT (TGP), GGT e Fosfatase Alcalina tiveram eleva√ß√£o acentuada no epis√≥dio de colestase.\nAgora parecem estabilizadas ou em leve queda, em linha com a resson√¢ncia (sem colangite aguda).\nO Tozacin pode estar ajudando a prevenir infec√ß√£o secund√°ria, enquanto a pr√≥pria PSC mant√©m as enzimas altas.\n\nBilirrubina:\n\nEst√° elevada, mas sem piora recente.\nBilirrubina est√°vel + PCR em queda √© sinal de que n√£o h√° piora obstrutiva/infecciosa no momento.\n\n\n\n\n\n\nA infec√ß√£o por C. difficile (in√≠cio de setembro) desencadeou inflama√ß√£o sist√™mica e provavelmente precipitou o flare da RCU.\nA PSC complicou o quadro: as enzimas subiram, mas a resson√¢ncia afastou nova obstru√ß√£o.\nOs m√©dicos entraram com antibi√≥tico de amplo espectro (Tozacin) para proteger contra colangite bacteriana ‚Äî conduta razo√°vel considerando seu hist√≥rico (colangite aguda no in√≠cio de agosto).\nAgora, os exames sugerem:\n\nInfec√ß√£o sob controle (queda de leuc√≥citos e PCR).\nColite ulcerativa ainda ativa, mas melhorando.\nPSC est√°vel, sem sinais de piora aguda.\n\n\n\n\n\n\nNesta semana: PCR e leuc√≥citos devem se aproximar da normalidade se a infec√ß√£o estiver realmente controlada.\n1‚Äì2 semanas: Enzimas hep√°ticas podem continuar altas, mas devem cair gradualmente se n√£o houver nova colangite.\nColite ulcerativa: a melhora pode demorar mais (algumas semanas), especialmente se houver ajuste de corticoide/biol√≥gicos.\nPSC: risco cr√¥nico ‚Äî objetivo √© estabilizar, n√£o normalizar completamente.\n\n\n\n\n\nSe enzimas hep√°ticas subirem novamente + febre ‚Üí suspeita de nova colangite.\nSe PCR n√£o cair ou plaquetas continuarem subindo ‚Üí pode indicar inflama√ß√£o cont√≠nua ou complica√ß√£o secund√°ria.\nSe bilirrubina aumentar muito ‚Üí pode haver nova obstru√ß√£o ou evento biliar.\n\n‚úÖ Resumo: Voc√™ est√° na fase de melhora da tempestade inflamat√≥ria/infecciosa: a C. diff e o flare da colite desencadearam o quadro, mas os antibi√≥ticos e o suporte hospitalar estabilizaram. A expectativa √© de melhora lenta e progressiva nas pr√≥ximas 1‚Äì2 semanas, desde que n√£o ocorra nova colangite ou reativa√ß√£o da RCU."
  },
  {
    "objectID": "reports/20241219_Colonoscopia.html",
    "href": "reports/20241219_Colonoscopia.html",
    "title": "Laudo",
    "section": "",
    "text": "Laudo\n\nProgress√£o do aparelho at√© o √≠leo terminal, sem intercorr√™ncias.\n‚ö†Ô∏è Em √≠leo distal, a cerca de 5cm da v√°lvula ileocecal, nota-se uma eros√£o puntiforme, com mucosa adjacente preservada. Realizada bi√≥psias (fr 01).\n‚ö†Ô∏è Em ceco, junto ao ap√™ndice cecal, nota-se √°rea com enantema, com microeros√µes, sugestiva de path cecal.Realizada bi√≥psias (fr 02).\n‚ö†Ô∏è Em c√≥lon ascendente, transverso, descendente e sigmoide, observa-se mucosa com aspecto cicatricial.\n‚ö†Ô∏è Em c√≥lon transverso distal e descendente, notam-se algumas √°reas com com edema, enantema e eros√µes entremadas por mucosa preservada.\n‚ö†Ô∏è Em c√≥lon transverso distal, nota-se uma √∫lcera rasa, medindo cerca de 10mm, recoberta por fibrina. Realizada bi√≥psias (fr04).\nReto sem altera√ß√µes."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Introduction",
    "section": "",
    "text": "Data, plots, timeline and journalling about my health management and battle with UC / PSC since January 2005. This grasping of data about myself, even if it gives just an illusion of control, it ‚Äúworks‚Äù nonetheless as coping mechanism because sometimes just the illusion is enough to calm down your monkey brain from taking over and the stress to worsen and even cause further malaise.\nThis is something I wanted to do for many years but never started. A recent double hospitalization in less than a month, and the advent of powerful LLM coding agents gave me the nudge I needed.\n\n\n\n\n\n\n\n\n\n\nPriority\nMain Mechanisms\nKey Compounds Involved\n\n\n\n\nLiver Support\nBile flow, detoxification, antioxidant protection\nUrsacol, Silymarin, NAC, Methionine, Choline, TMG, SAMe, Taurine, Omega-3, MSM, Vitamin K2\n\n\nAnti-inflammatory Control (Systemic + Colon)\nCytokine modulation, gut barrier repair\nAdalimumab, Mesalazine, Omega-3, Curcumin (Golden Milk), Quercetin, Boswellia, Psyllium, Probiotics\n\n\nSleep Optimization\nGABAergic, serotonin, and glycine pathways\nMagnesium (bisglycinate/taurinate), Theanine, Melatonin, Glycine, Inositol\n\n\n\n\n\n\n\n\n\nMechanism: Hydrophilic bile acid ‚Üí replaces toxic bile salts ‚Üí reduces cholestasis & inflammation in PSC.\nDose: Currently 2 √ó 300 mg (AM) + 3 √ó 300 mg (bedtime) = 1.5 g/day (align with weight‚Äëbased guidance with your hepatologist).\nOptimization: Maintain split dosing (AM + bedtime).\n\n\n\n\n\n2 √ó 200 mg at lunch + 2 √ó 200 mg at bedtime (= 800 mg/day). Hepatoprotection via glutathione up‚Äëregulation and NF‚ÄëŒ∫B modulation.\n\n\n\n\n\n1.5 g lunch + 1.5 g bedtime ‚Üí hepatic GSH support and mucosal protection.\n\n\n\n\n\n2 g lunch + 2 g bedtime ‚Üí thiol replenishment & connective‚Äëtissue support.\n\n\n\n\n\nSupports BHMT remethylation and may aid bile flow; complements methionine/choline.\n\n\n\n\n\nEvidence for cholestasis symptom and enzyme support; avoid late‚Äëevening dosing if stimulating.\n\n\n\n\n\nSubstrate for bile‚Äëacid conjugation; supportive for bile flow.\n\n\n\n\n\nFat‚Äësoluble vitamin support in cholestasis (bone/INR considerations). Water‚Äëmiscible forms if advised.\n\n\n\n\n\n\n\n\nBaseline for mucosal control ‚Äî continue as prescribed.\n\n\n\n\n\nLipid vehicle (milk) + piperine improves absorption.\n\n\n\n\n\nAt lunch per schedule; maintain split EPA+DHA to ~3 g/day total.\n\n\n\n\n\nRemission maintenance and butyrate support. Separate from meds/supps by ~2 h (iron, calcium, NAC, quercetin, mesalazine).\n\n\n\n\n\nL. rhamnosus + NutrioneLife at dinner.\n\nStep‚Äëup options: De Simone formulation (VSL#3) or E. coli Nissle 1917 (Mutaflor) ‚Äî in afternoon, ‚â•3‚Äì4 h after Bactrim.\n\n\n\n\n\nAnti‚Äëinflammatory/anti‚Äëfibrotic; keep ‚â•3 h away from iron (Noripurum).\n\n\n\n\n\nBotanical adjunct for UC inflammation/fibrosis; use standardized extract.\n\n\n\n\n\n\n\n\nSleep onset/maintenance; titrate by 0.5‚Äì1 mg steps.\n\n\n\n\n\nImproves slow‚Äëwave sleep and thermoregulation.\n\n\n\n\n\nSerotonergic/cholinergic modulation for calmer sleep.\n\n\n\n\n\nKeep 100‚Äì150 mg mid‚Äëafternoon + remainder at bedtime if helpful for wind‚Äëdown.\n\n\n\n\n\nKeep morning + pre‚Äëbed; avoid high citrate late day if it loosens stools. ## üß© 5. Quercetin Integration\n\nDosing in schedule: 500 mg lunch + 500 mg bedtime.\n* Roles: anti‚Äëinflammatory, mast‚Äëcell stabilizer, antifibrotic.\n* Spacing: keep ‚â•3 h away from iron; avoid taking with large calcium/fiber boluses that impair absorption.\n\n\n\n\n\n\n\nüçé Apple Cider Vinegar ‚Äî 1‚Äì3 tbsp (diluted)\n‚ö° Magnesium complex ‚Äî 2 x 117 mg\nüíä Bactrim ‚Äî 1 tab\nüíä Ursacol ‚Äî 2 x 300 mg\nüçµ Theanine ‚Äî 250 mg\nüèãÔ∏è Creatine ‚Äî 10 g\nüß¨ TMG (Trimethylglycine) ‚Äî 500 mg\nüß™ SAMe (S-adenosyl-L-methionine) ‚Äî 400 mg\nüß™ Taurine ‚Äî 1 g\nüíä Mesalazine ‚Äî 1 x 500 mg\nüíâ Adalimumab ‚Äî 1 x 40 mg (weekly)\n\n\n\n\n\n\nüåû Vitamin D3 ‚Äî 2 x 2000 IU\nüêü Omega-3 + üß† Phosphatidylserine ‚Äî 2 x 0.8 g | 2 x 50 mg\nüï∏Ô∏è NAC ‚Äî 1.5 g\nüï∏Ô∏è Racemethionine + Choline ‚Äî 2 x (100 mg + 20 mg)\nüï∏Ô∏è Silymarin ‚Äî 2 x 200 mg\nüõ°Ô∏è Quercetin ‚Äî 1 x 500 mg\nü¶¥ Calcium ‚Äî 1 x 500 mg\nü¶µ MSM ‚Äî 2 g\n\n\n\n\n\n\n‚ú® Golden Milk ‚Äî 15 g (with pepper)\nüçä Vitamin C ‚Äî 1 g\nüî© Noripurum ‚Äî 20 drops (20 mg Fe) ‚Üí avoid 2‚Äì3 h around quercetin/NAC/calcium\nL. rhamnosus ‚Äî 2 sachets (250 mg)\nüß™ SAMe (S-adenosyl-L-methionine) ‚Äî 400 mg\n\n\n\n\n\n\nü¶† NutrioneLife ‚Äî 1 sachet\nü¶¥ Vitamin K2 (MK-7) ‚Äî 100‚Äì200 ¬µg\nüï∏Ô∏è Racemethionine + Choline ‚Äî 2 x (100 mg + 20 mg)\nüß™ Taurine ‚Äî 1 g\nüß¨ TMG (Trimethylglycine) ‚Äî 500 mg\n\n\n\n\n\n\nüåô Melatonin ‚Äî 1‚Äì3 mg (start 1 mg)\nüíä Ursacol ‚Äî 3 x 300 mg (900 mg)\nüí§ Glycine ‚Äî 3 g\nüí§ Myo-Inositol ‚Äî 3 g\nüï∏Ô∏è Silymarin ‚Äî 2 x 200 mg\nüõ°Ô∏è NAC ‚Äî 1.5 g\nüõ°Ô∏è Quercetin ‚Äî 1 x 500 mg\nü¶µ MSM ‚Äî 2 g\n\n\n\n\n\n\n\n\n\n\n\n\n\nFocus\nRecommendation\n\n\n\n\nIron absorption\nMaintain Noripurum away from quercetin, NAC, and calcium.\n\n\nBowel motility\nIf stools become too loose, shift part of magnesium dose earlier or reduce citrate fraction.\n\n\nMethylation balance\nYou are using TMG 500 mg AM + 500 mg dinner for methyl‚Äëcycle support.\n\n\nInflammatory control\nCurcumin + Omega-3 + Adalimumab + Quercetin + Silymarin create an excellent anti-NF-Œ∫B network; avoid unnecessary NSAIDs.\n\n\nSleep\nMaintain fixed bedtime, dim light 1 h before, magnesium/glycine/theanine/inositol at least 30 min pre-sleep.\n\n\n\n\n\n\n\n\n‚úÖ Strong hepatoprotection: Ursacol + Silymarin + NAC + MSM\n‚úÖ Anti-inflammatory synergy: Adalimumab + Omega-3 + Curcumin + Quercetin\n‚úÖ Sleep foundation: Magnesium bisglycinate + Theanine + Glycine + Inositol\n‚ö†Ô∏è Manage supplement timing to avoid absorption conflicts (iron ‚ÜîÔ∏é quercetin/NAC).\n‚öôÔ∏è Optionally recheck hepatic enzymes (Œ≥-GT, ALP) after 6‚Äì8 weeks on this adjusted plan to quantify benefit."
  },
  {
    "objectID": "index.html#overview-of-goals",
    "href": "index.html#overview-of-goals",
    "title": "Introduction",
    "section": "",
    "text": "Priority\nMain Mechanisms\nKey Compounds Involved\n\n\n\n\nLiver Support\nBile flow, detoxification, antioxidant protection\nUrsacol, Silymarin, NAC, Methionine, Choline, TMG, SAMe, Taurine, Omega-3, MSM, Vitamin K2\n\n\nAnti-inflammatory Control (Systemic + Colon)\nCytokine modulation, gut barrier repair\nAdalimumab, Mesalazine, Omega-3, Curcumin (Golden Milk), Quercetin, Boswellia, Psyllium, Probiotics\n\n\nSleep Optimization\nGABAergic, serotonin, and glycine pathways\nMagnesium (bisglycinate/taurinate), Theanine, Melatonin, Glycine, Inositol"
  },
  {
    "objectID": "index.html#liver-biliary-support",
    "href": "index.html#liver-biliary-support",
    "title": "Introduction",
    "section": "",
    "text": "Mechanism: Hydrophilic bile acid ‚Üí replaces toxic bile salts ‚Üí reduces cholestasis & inflammation in PSC.\nDose: Currently 2 √ó 300 mg (AM) + 3 √ó 300 mg (bedtime) = 1.5 g/day (align with weight‚Äëbased guidance with your hepatologist).\nOptimization: Maintain split dosing (AM + bedtime).\n\n\n\n\n\n2 √ó 200 mg at lunch + 2 √ó 200 mg at bedtime (= 800 mg/day). Hepatoprotection via glutathione up‚Äëregulation and NF‚ÄëŒ∫B modulation.\n\n\n\n\n\n1.5 g lunch + 1.5 g bedtime ‚Üí hepatic GSH support and mucosal protection.\n\n\n\n\n\n2 g lunch + 2 g bedtime ‚Üí thiol replenishment & connective‚Äëtissue support.\n\n\n\n\n\nSupports BHMT remethylation and may aid bile flow; complements methionine/choline.\n\n\n\n\n\nEvidence for cholestasis symptom and enzyme support; avoid late‚Äëevening dosing if stimulating.\n\n\n\n\n\nSubstrate for bile‚Äëacid conjugation; supportive for bile flow.\n\n\n\n\n\nFat‚Äësoluble vitamin support in cholestasis (bone/INR considerations). Water‚Äëmiscible forms if advised."
  },
  {
    "objectID": "index.html#anti-inflammatory-gut-support",
    "href": "index.html#anti-inflammatory-gut-support",
    "title": "Introduction",
    "section": "",
    "text": "Baseline for mucosal control ‚Äî continue as prescribed.\n\n\n\n\n\nLipid vehicle (milk) + piperine improves absorption.\n\n\n\n\n\nAt lunch per schedule; maintain split EPA+DHA to ~3 g/day total.\n\n\n\n\n\nRemission maintenance and butyrate support. Separate from meds/supps by ~2 h (iron, calcium, NAC, quercetin, mesalazine).\n\n\n\n\n\nL. rhamnosus + NutrioneLife at dinner.\n\nStep‚Äëup options: De Simone formulation (VSL#3) or E. coli Nissle 1917 (Mutaflor) ‚Äî in afternoon, ‚â•3‚Äì4 h after Bactrim.\n\n\n\n\n\nAnti‚Äëinflammatory/anti‚Äëfibrotic; keep ‚â•3 h away from iron (Noripurum).\n\n\n\n\n\nBotanical adjunct for UC inflammation/fibrosis; use standardized extract."
  },
  {
    "objectID": "index.html#sleep-optimization",
    "href": "index.html#sleep-optimization",
    "title": "Introduction",
    "section": "",
    "text": "Sleep onset/maintenance; titrate by 0.5‚Äì1 mg steps.\n\n\n\n\n\nImproves slow‚Äëwave sleep and thermoregulation.\n\n\n\n\n\nSerotonergic/cholinergic modulation for calmer sleep.\n\n\n\n\n\nKeep 100‚Äì150 mg mid‚Äëafternoon + remainder at bedtime if helpful for wind‚Äëdown.\n\n\n\n\n\nKeep morning + pre‚Äëbed; avoid high citrate late day if it loosens stools. ## üß© 5. Quercetin Integration\n\nDosing in schedule: 500 mg lunch + 500 mg bedtime.\n* Roles: anti‚Äëinflammatory, mast‚Äëcell stabilizer, antifibrotic.\n* Spacing: keep ‚â•3 h away from iron; avoid taking with large calcium/fiber boluses that impair absorption."
  },
  {
    "objectID": "index.html#adjusted-schedule-summary",
    "href": "index.html#adjusted-schedule-summary",
    "title": "Introduction",
    "section": "",
    "text": "üçé Apple Cider Vinegar ‚Äî 1‚Äì3 tbsp (diluted)\n‚ö° Magnesium complex ‚Äî 2 x 117 mg\nüíä Bactrim ‚Äî 1 tab\nüíä Ursacol ‚Äî 2 x 300 mg\nüçµ Theanine ‚Äî 250 mg\nüèãÔ∏è Creatine ‚Äî 10 g\nüß¨ TMG (Trimethylglycine) ‚Äî 500 mg\nüß™ SAMe (S-adenosyl-L-methionine) ‚Äî 400 mg\nüß™ Taurine ‚Äî 1 g\nüíä Mesalazine ‚Äî 1 x 500 mg\nüíâ Adalimumab ‚Äî 1 x 40 mg (weekly)\n\n\n\n\n\n\nüåû Vitamin D3 ‚Äî 2 x 2000 IU\nüêü Omega-3 + üß† Phosphatidylserine ‚Äî 2 x 0.8 g | 2 x 50 mg\nüï∏Ô∏è NAC ‚Äî 1.5 g\nüï∏Ô∏è Racemethionine + Choline ‚Äî 2 x (100 mg + 20 mg)\nüï∏Ô∏è Silymarin ‚Äî 2 x 200 mg\nüõ°Ô∏è Quercetin ‚Äî 1 x 500 mg\nü¶¥ Calcium ‚Äî 1 x 500 mg\nü¶µ MSM ‚Äî 2 g\n\n\n\n\n\n\n‚ú® Golden Milk ‚Äî 15 g (with pepper)\nüçä Vitamin C ‚Äî 1 g\nüî© Noripurum ‚Äî 20 drops (20 mg Fe) ‚Üí avoid 2‚Äì3 h around quercetin/NAC/calcium\nL. rhamnosus ‚Äî 2 sachets (250 mg)\nüß™ SAMe (S-adenosyl-L-methionine) ‚Äî 400 mg\n\n\n\n\n\n\nü¶† NutrioneLife ‚Äî 1 sachet\nü¶¥ Vitamin K2 (MK-7) ‚Äî 100‚Äì200 ¬µg\nüï∏Ô∏è Racemethionine + Choline ‚Äî 2 x (100 mg + 20 mg)\nüß™ Taurine ‚Äî 1 g\nüß¨ TMG (Trimethylglycine) ‚Äî 500 mg\n\n\n\n\n\n\nüåô Melatonin ‚Äî 1‚Äì3 mg (start 1 mg)\nüíä Ursacol ‚Äî 3 x 300 mg (900 mg)\nüí§ Glycine ‚Äî 3 g\nüí§ Myo-Inositol ‚Äî 3 g\nüï∏Ô∏è Silymarin ‚Äî 2 x 200 mg\nüõ°Ô∏è NAC ‚Äî 1.5 g\nüõ°Ô∏è Quercetin ‚Äî 1 x 500 mg\nü¶µ MSM ‚Äî 2 g"
  },
  {
    "objectID": "index.html#strategic-observations",
    "href": "index.html#strategic-observations",
    "title": "Introduction",
    "section": "",
    "text": "Focus\nRecommendation\n\n\n\n\nIron absorption\nMaintain Noripurum away from quercetin, NAC, and calcium.\n\n\nBowel motility\nIf stools become too loose, shift part of magnesium dose earlier or reduce citrate fraction.\n\n\nMethylation balance\nYou are using TMG 500 mg AM + 500 mg dinner for methyl‚Äëcycle support.\n\n\nInflammatory control\nCurcumin + Omega-3 + Adalimumab + Quercetin + Silymarin create an excellent anti-NF-Œ∫B network; avoid unnecessary NSAIDs.\n\n\nSleep\nMaintain fixed bedtime, dim light 1 h before, magnesium/glycine/theanine/inositol at least 30 min pre-sleep."
  },
  {
    "objectID": "index.html#key-takeaways",
    "href": "index.html#key-takeaways",
    "title": "Introduction",
    "section": "",
    "text": "‚úÖ Strong hepatoprotection: Ursacol + Silymarin + NAC + MSM\n‚úÖ Anti-inflammatory synergy: Adalimumab + Omega-3 + Curcumin + Quercetin\n‚úÖ Sleep foundation: Magnesium bisglycinate + Theanine + Glycine + Inositol\n‚ö†Ô∏è Manage supplement timing to avoid absorption conflicts (iron ‚ÜîÔ∏é quercetin/NAC).\n‚öôÔ∏è Optionally recheck hepatic enzymes (Œ≥-GT, ALP) after 6‚Äì8 weeks on this adjusted plan to quantify benefit."
  },
  {
    "objectID": "WARP.html",
    "href": "WARP.html",
    "title": "WARP.md",
    "section": "",
    "text": "This file provides guidance to WARP (warp.dev) when working with code in this repository.\n\n\nmaladie is a health data visualization dashboard for analyzing time series blood marker data. It‚Äôs a single-page web application that creates interactive charts from CSV health data, allowing users to track biomarker evolution over time and identify out-of-range values.\n\n\n\n\n\n\nmain: Basic project setup (README, LICENSE)\nchart: Contains the complete application code and data\n\n\n\n\n\nindex.html: Complete interactive dashboard with embedded CSS/JavaScript\nblood_markers_pivot.csv: Health data in pivot format (columns are dates, rows are analytes)\n\n\n\n\n\n\n\n\nInput Format: CSV with analytes as rows, datetime columns, and reference ranges\nData Categories: Organized into functional groups (Inflammatory, Hematology, Kidney, Liver, etc.)\nValue Handling: Supports numeric values, special markers (‚Äú‚Äî-‚Äù, ‚ÄúInferior a 0.5‚Äù, ‚ÄúRaras‚Äù)\n\n\n\n\n\nTechnology: Pure HTML/CSS/JavaScript with Plotly.js for charting\nLoading: Automatic CSV loading with fallback to manual file picker\nVisualization: Interactive time series with reference ranges, historical min/max, median trends\nAnalysis: Real-time detection of out-of-range values with percentage deviations\n\n\n\n\n\nInteractive Charts: Zoom, pan, range slider for temporal navigation\nReference Ranges: Visual indication with green shaded areas\nTrend Analysis: Historical minimum/maximum lines, median trends\nFocus Box: Highlights latest out-of-range measurements with directional arrows\nData Export: Both pivot table and tidy format CSV downloads\nResponsive Design: Mobile-friendly interface\n\n\n\n\n\n\n\n# Serve locally (required due to CORS restrictions with CSV loading)\nuv run python -m http.server 8000\n# Then open http://localhost:8000/index.html\n\n\n\n# Switch to chart branch where code lives\ngit checkout chart\n\n# Check data structure\nhead blood_markers_pivot.csv\n\n# View recent changes to data\ngit --no-pager log --oneline -10\n\n\n\nThe project expects CSV data in a specific pivot format: - First column: Analyte names - Middle columns: DateTime values (DD/MM/YY HH:MM format)\n- Last column: Reference ranges with units - Values can be numeric, ‚Äú‚Äî-‚Äù (missing), or special text values\n\n\n\n# Start local server for testing\nuv run python -m http.server 8000\n\n# View application at:\n# http://localhost:8000/index.html\n\n\n\n\nThe application organizes analytes into functional groups: - Inflammatory: Prote√≠na C reativa, Calprotectina\n- Hematology: Complete blood count parameters - Kidney: Creatinina, Ureia - Liver: Liver function tests (TGO, TGP, Bilirubin, etc.) - Electrolytes/Minerals: Sodium, Potassium, Calcium, etc. - Lipids: Cholesterol panel - Hormones: Thyroid, reproductive hormones - Vitamins: B12, Folate, Vitamin D\n\n\n\n\nRequires modern browser with ES6+ support\nUses Plotly.js CDN for charting\nImplements manual file picker fallback for local file:// access\n\n\n\n\n\nNo server-side storage or processing\nAll analysis happens client-side\nPatient information should be anonymized in CSV data"
  },
  {
    "objectID": "WARP.html#project-overview",
    "href": "WARP.html#project-overview",
    "title": "WARP.md",
    "section": "",
    "text": "maladie is a health data visualization dashboard for analyzing time series blood marker data. It‚Äôs a single-page web application that creates interactive charts from CSV health data, allowing users to track biomarker evolution over time and identify out-of-range values."
  },
  {
    "objectID": "WARP.html#repository-structure",
    "href": "WARP.html#repository-structure",
    "title": "WARP.md",
    "section": "",
    "text": "main: Basic project setup (README, LICENSE)\nchart: Contains the complete application code and data\n\n\n\n\n\nindex.html: Complete interactive dashboard with embedded CSS/JavaScript\nblood_markers_pivot.csv: Health data in pivot format (columns are dates, rows are analytes)"
  },
  {
    "objectID": "WARP.html#key-architecture",
    "href": "WARP.html#key-architecture",
    "title": "WARP.md",
    "section": "",
    "text": "Input Format: CSV with analytes as rows, datetime columns, and reference ranges\nData Categories: Organized into functional groups (Inflammatory, Hematology, Kidney, Liver, etc.)\nValue Handling: Supports numeric values, special markers (‚Äú‚Äî-‚Äù, ‚ÄúInferior a 0.5‚Äù, ‚ÄúRaras‚Äù)\n\n\n\n\n\nTechnology: Pure HTML/CSS/JavaScript with Plotly.js for charting\nLoading: Automatic CSV loading with fallback to manual file picker\nVisualization: Interactive time series with reference ranges, historical min/max, median trends\nAnalysis: Real-time detection of out-of-range values with percentage deviations\n\n\n\n\n\nInteractive Charts: Zoom, pan, range slider for temporal navigation\nReference Ranges: Visual indication with green shaded areas\nTrend Analysis: Historical minimum/maximum lines, median trends\nFocus Box: Highlights latest out-of-range measurements with directional arrows\nData Export: Both pivot table and tidy format CSV downloads\nResponsive Design: Mobile-friendly interface"
  },
  {
    "objectID": "WARP.html#common-development-tasks",
    "href": "WARP.html#common-development-tasks",
    "title": "WARP.md",
    "section": "",
    "text": "# Serve locally (required due to CORS restrictions with CSV loading)\nuv run python -m http.server 8000\n# Then open http://localhost:8000/index.html\n\n\n\n# Switch to chart branch where code lives\ngit checkout chart\n\n# Check data structure\nhead blood_markers_pivot.csv\n\n# View recent changes to data\ngit --no-pager log --oneline -10\n\n\n\nThe project expects CSV data in a specific pivot format: - First column: Analyte names - Middle columns: DateTime values (DD/MM/YY HH:MM format)\n- Last column: Reference ranges with units - Values can be numeric, ‚Äú‚Äî-‚Äù (missing), or special text values\n\n\n\n# Start local server for testing\nuv run python -m http.server 8000\n\n# View application at:\n# http://localhost:8000/index.html"
  },
  {
    "objectID": "WARP.html#data-categories-and-groupings",
    "href": "WARP.html#data-categories-and-groupings",
    "title": "WARP.md",
    "section": "",
    "text": "The application organizes analytes into functional groups: - Inflammatory: Prote√≠na C reativa, Calprotectina\n- Hematology: Complete blood count parameters - Kidney: Creatinina, Ureia - Liver: Liver function tests (TGO, TGP, Bilirubin, etc.) - Electrolytes/Minerals: Sodium, Potassium, Calcium, etc. - Lipids: Cholesterol panel - Hormones: Thyroid, reproductive hormones - Vitamins: B12, Folate, Vitamin D"
  },
  {
    "objectID": "WARP.html#browser-compatibility",
    "href": "WARP.html#browser-compatibility",
    "title": "WARP.md",
    "section": "",
    "text": "Requires modern browser with ES6+ support\nUses Plotly.js CDN for charting\nImplements manual file picker fallback for local file:// access"
  },
  {
    "objectID": "WARP.html#data-privacy",
    "href": "WARP.html#data-privacy",
    "title": "WARP.md",
    "section": "",
    "text": "No server-side storage or processing\nAll analysis happens client-side\nPatient information should be anonymized in CSV data"
  }
]